Analysis of lung injury models by using human MUC1 transgenic mice.
| Project/Area Number |
25461191
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Kochi University |
|---|
Principal Investigator |
KUBOTA TETSUYA 高知大学, 教育研究部医療学系臨床医学部門, 准教授 (30274377)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOKOYAMA Akihito 高知大学, 教育研究部医療学系臨床医学部門, 教授 (30191513)
OHNISHI Hiroshi 高知大学, 教育研究部医療学系臨床医学部門, 助教 (90553876)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SAKAI Mizu 高知大学, 教育研究部医療学系臨床医学部門, 助教 (40403886)
KAWASE Shigeo 高知大学, 教育研究部医療学系臨床医学部門, 助教 (80642058)
MIYAMOTO Shintaro 高知大学, 教育研究部医療学系臨床医学部門, 助教 (30633995)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | KL-6 / MUC1 / 間質性肺炎 / 肺障害 / 動物モデル / バイオマーカー |
|---|
| Outline of Final Research Achievements |
KL-6, an epitope of MUC1 expressed mainly on type II pneumocytes in humans, is a sensitive marker for interstitial pneumonia. However, an in vivo model for KL-6 has not been established because no KL-6 epitope is expressed in animals other than humans and apes. To investigate whether KL-6 is detectable in human MUC1 transgenic mice and whether KL-6 level reflects the degree of lung injury, we examined levels of KL-6 and other biomarkers in a variety of lung injury models. KL-6 was expressed on type II pneumocytes and bronchiolar epithelial cells in naive hMUC1-Tg mice. Serum KL-6 levels in these mice were comparable to those in humans, and KL-6 levels in BALF were significantly higher than those in sera. Levels of KL-6 dramatically changed depending on the variety and severity of lung injuries, suggesting its function as a biomarker in hMUC1-Tg mice. KL-6 behaved differently from other biomarkers. This hMUC1-Tg mouse can be used for assessment of KL-6 in vivo during lung injury.
|
Report
(4 results)
Research Products
(9 results)
-
[Journal Article] Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-Small Cell Lung Cancer.2016
Author(s)
Tetsuya Kubota, Yoshio Okano, Mizu Sakai, Masato Takaoka, Tsukie Tsukuda, Kazuki Anabuki, Shigeo Kawase, Shintaro Miyamoto, Hiroshi Ohnishi, Nobuo Hatakeyama, Hisanori Machida, Tomoyuki Urata, Akira Yamamoto, Fumitaka Ogushi, Akihito Yokoyama
-
Journal Title
Anticancer Research
Volume: 36
Pages: 307-312
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
